NASDAQ:CRSP • CH0334081137
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CRISPR THERAPEUTICS AG (CRSP).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-17 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2026-02-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-02-13 | TD Cowen | Maintains | Hold -> Hold |
| 2026-02-13 | Needham | Maintains | Buy -> Buy |
| 2026-02-13 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-01-30 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-12-23 | Citizens | Reiterate | Market Outperform -> Market Outperform |
| 2025-12-23 | Needham | Reiterate | Buy -> Buy |
| 2025-11-26 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-12 | Citigroup | Maintains | Buy -> Buy |
| 2025-11-11 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-11-11 | Baird | Maintains | Neutral -> Neutral |
| 2025-11-10 | Needham | Maintains | Buy -> Buy |
| 2025-10-17 | B of A Securities | Maintains | Buy -> Buy |
| 2025-10-10 | Needham | Reiterate | Buy -> Buy |
| 2025-09-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-18 | JP Morgan | Initiate | Overweight |
| 2025-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-06 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-05 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-07-22 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-08 | Needham | Reiterate | Buy -> Buy |
| 2025-06-27 | Clear Street | Downgrade | Buy -> Hold |
| 2025-06-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 371.206M 30,833.83% | 37.314M -89.95% | 3.51M -90.59% | 41.509M 1,082.59% | 77.93M 87.74% | 626.29M 703.66% | 2.399B 283.05% | 6.085B 153.65% | 1.182B -80.58% | 1.569B 32.74% | 1.868B 19.06% | |
| EBITDA YoY % growth | -202.701M 68.77% | -447.307M -120.67% | -548.839M -22.70% | -472.956M 13.83% | -449.386M 4.98% | -333.509M 25.79% | 258.36M 177.47% | 463.08M 79.24% | 569.16M 22.91% | 1.132B 98.89% | 1.607B 41.96% | |
| EBIT YoY % growth | -222.538M 66.94% | -466.566M -109.66% | -568.318M -21.81% | -528.915M 6.93% | -500.476M 5.38% | -233.008M 53.44% | -117.153M 49.72% | 90.751M 177.46% | 432.74M 376.84% | 761.33M 75.93% | 1.012B 32.93% | |
| Operating Margin | -59.95% | -1,250.38% | -16,191.40% | -1,274.22% | -642.21% | -37.20% | -4.88% | 1.49% | 36.61% | 48.52% | 54.18% | |
| EPS YoY % growth | -1.96 76.58% | -4.37 -122.96% | -5.41 -23.80% | -5.02 7.20% | -4.16 17.13% | -1.82 56.17% | -0.99 45.51% | 1.04 205.13% | 4.42 323.42% | 7.32 65.38% | 9.55 30.53% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.25 20.85% | -1.25 3.41% | -1.05 9.99% | -1.03 25.07% |
| Revenue Q2Q % growth | 1.863M 115.38% | 5.154M 477.80% | 17.026M 1,815.19% | 21.877M 2,432.06% |
| EBITDA Q2Q % growth | -115.785M 19.42% | -109M 11.87% | -119.534M -1.09% | N/A |
| EBIT Q2Q % growth | -139.072M 6.30% | -139.751M -5.02% | -109.878M 16.80% | -123.807M 20.00% |
All data in USD
35 analysts have analysed CRSP and the average price target is 84.28 USD. This implies a price increase of 76.47% is expected in the next year compared to the current price of 47.76.
CRISPR THERAPEUTICS AG (CRSP) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of CRISPR THERAPEUTICS AG (CRSP) is -1.25 USD and the consensus revenue estimate is 1.86M USD.
The consensus rating for CRISPR THERAPEUTICS AG (CRSP) is 77.1429 / 100 . This indicates that analysts generally have a positive outlook on the stock.